Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues1.9b2.4b2.9b3.6b4.0b4.6b5.4b
% growth31 %27 %19 %24 %11 %15 %16 %
EBITDA383m277m417m917m1.2b1.4b1.7b
% EBITDA margin20 %11 %14 %25 %29 %31 %32 %
Profit494m155m341m542m670m806m985m
% profit margin26 %6 %12 %15 %17 %17 %18 %
EV / revenue18.9x21.5x15.5x13.8x7.2x6.1x5.1x
EV / EBITDA95.0x189.9x108.1x54.3x24.9x20.1x16.1x
R&D budget360m604m484m506m---
R&D % of revenue19 %25 %17 %14 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-

$30.0m

Series C

$22.5m

Series D
N/A

N/A

IPO
N/A

$4.0m

Post IPO Equity

$220k

Grant
N/A

$7.2m

Post IPO Equity
N/A

$350m

Post IPO Debt
*
N/A

$850m

Post IPO Convertible
*
N/A

$158m

Post IPO Convertible
*
N/A

$1.0b

Post IPO Convertible
Total Funding$52.7m

Recent News about Dexcom

Edit
More about Dexcominfo icon
Edit

Dexcom, Inc. specializes in developing and marketing continuous glucose monitoring (CGM) systems for diabetes management. The company's core product, the Dexcom G6 CGM System, provides real-time glucose readings to patients, allowing them to manage their condition more effectively. Dexcom serves a diverse client base, including individuals with diabetes, healthcare providers, and caregivers. Operating in the global healthcare market, Dexcom's business model revolves around the sale of CGM devices and related software applications, such as Dexcom CLARITY, which offers data analytics and insights. Revenue is primarily generated through the sale of these devices and subscription-based services for data management. Dexcom's innovative technology aims to improve the quality of life for diabetes patients by offering accurate, easy-to-use glucose monitoring solutions.

Keywords: continuous glucose monitoring, diabetes management, real-time data, Dexcom G6, healthcare, glucose readings, CGM devices, data analytics, subscription services, patient care.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Dexcom

Edit
SweetSpot Diabetes Care
ACQUISITION by Dexcom Feb 2012
TypeZero Technologies
ACQUISITION by Dexcom Aug 2018
Nintamed
ACQUISITION by Dexcom May 2016